This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Kenji Kubara
Scientist, Emerging Modality Generation at Eisai. Co., Ltd.


Kenji Kubara is a scientist at Eisai Tsukuba Research Laboratories. He graduated from Kyushu University and joined Eisai in 2009. He has been working on development of biological technologies including iPS cells, genome editing, and nucleic acid delivery. Recently, he focuses on development of mRNA delivery system and research on immunological mechanisms of mRNA vaccine.

Agenda Sessions

  • Lymph Node Macrophages Drive Innate Immune Responses to Enhance the Anti-tumor Efficacy of mRNA Vaccines